Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

JPMorgan reinstates coverage on Serco at 'overweight'

(Sharecast News) - JPMorgan Cazenove reinstated coverage on Serco on Monday with an 'overweight' rating and a target price of 215p.

The bank said its analysis suggests that Serco can generate double-digit earnings per share growth in the medium term.

"Firstly, Serco's revenue growth (target 4-6%) is largely acyclical, given the exclusive focus on government customers," it said.

"Serco's strategy has been to expand further into attractive target markets, with a particular emphasis on US defence (deepening the current Navy focus and winning work elsewhere, e.g., with the Air Force/Space Force) as well as US civilian Federal services.

"Second, we see scope for margins to improve further, chiefly due to an improving mix (higher US exposure) and also due to a greater focus on contract profitability management (a key priority for this management team as evidenced in the 1H24 results).

"Third, Serco can continue to utilise its FCF for M&A and buybacks."

Citi said it used a discounted cash flow to derive its target price, but also considered a sum-of-the-parts approach that suggests Serco's current valuation does not give the stock full credit for its US defence exposure, giving circa 30% upside potential.

Share this article

Related Sharecast Articles

Smith & Nephew appoints Ajay Dhankhar as chief corporate development & strategy officer
(Sharecast News) - Medical technology company Smith & Nephew said on Monday that it has appointed Ajay Dhankhar as chief corporate development & strategy officer with immediate effect.
Oxford Biomedica acquires last 10pc stake in US subsidiary
(Sharecast News) - Oxford Biomedica said on Monday it has acquired the remaining 10% stake in its US subsidiary, OXB US, from Q32 Bio, bringing its ownership of the business to 100% as previously planned.
PPHE acquiring prime London site for hotel development
(Sharecast News) - PPHE Hotel Group has announced the acquisition of a prime development site near the City of London, where it plans to build its first Radisson RED select service hotel in the capital.
Norcros to end tile production in South Africa
(Sharecast News) - Norcros announced on Monday that it will shut down manufacturing at Johnson Tiles South Africa at the end of June, following the conclusion of a strategic review.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.